Difference between revisions of "Adult T-cell leukemia-lymphoma - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "0 PubMed]" to "0/ PubMed]")
m (Text replacement - "As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. " to "")
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Adult T-cell leukemia-lymphoma|main ATCLL page]] for current regimens.
+
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[Adult T-cell leukemia-lymphoma|main ATCLL page]] for current regimens.
  
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
+
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
+
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}  
 
|}  
  
Line 11: Line 11:
 
=Untreated=
 
=Untreated=
 
==Interferon alfa-2b & Zidovudine {{#subobject:cd558b|Regimen=1}}==
 
==Interferon alfa-2b & Zidovudine {{#subobject:cd558b|Regimen=1}}==
−
 
+
<div class="toccolours" style="background-color:#ee6b6e">
 
===Regimen {{#subobject:b1307e|Variant=1}}===
 
===Regimen {{#subobject:b1307e|Variant=1}}===
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
Line 20: Line 20:
 
|[https://doi.org/10.1056/NEJM199506293322603 Gill et al. 1995]
 
|[https://doi.org/10.1056/NEJM199506293322603 Gill et al. 1995]
 
|NR
 
|NR
−
| style="background-color:#ffffbe" |Non-randomized, <20 pts
+
| style="background-color:#ffffbe" |Non-randomized, fewer than 20 pts
 
|-
 
|-
 
|}
 
|}
−
''Of historic interest.''
+
<div class="toccolours" style="background-color:#b3e2cd">
 
====Immunotherapy====
 
====Immunotherapy====
−
*[[Interferon alfa-2b (Intron-A)]]
+
*[[Interferon alfa-2b (Intron-A)]] as follows:
−
*[[Zidovudine (Retrovir)]]
+
**Cycle 1: 5,000,000 units SC once per day on days 1 to 7
 +
**Cycles 2 to 52: 10,000,000 units SC once per day on days 1 to 7
 +
*[[Zidovudine (Retrovir)]] 200 mg PO five times per day
 +
'''7-day cycle for up to 52 cycles or at least 4 cycles past documented CR'''
 +
</div></div>
 
===References===
 
===References===
−
# Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995 Jun 29;332(26):1744-8. [https://doi.org/10.1056/NEJM199506293322603 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7760890/ PubMed]
+
# Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995 Jun 29;332(26):1744-8. [https://doi.org/10.1056/NEJM199506293322603 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/7760890/ PubMed]
  
 
==LSG15 {{#subobject:96c8e2|Regimen=1}}==
 
==LSG15 {{#subobject:96c8e2|Regimen=1}}==
−
 
+
<div class="toccolours" style="background-color:#ee6b6e">
−
 
 
 
===Regimen {{#subobject:2fae5f|Variant=1}}===
 
===Regimen {{#subobject:2fae5f|Variant=1}}===
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
Line 44: Line 47:
 
|-
 
|-
 
|}
 
|}
−
''Ranimustine is not available in the United States and is approved only in Japan. This regimen was notable for excess CNS relapses and was subsequently replaced by [[#mLSG15|mLSG15]].''
+
''Note: Ranimustine is not available in the United States and is approved only in Japan. This regimen was notable for excess CNS relapses and was subsequently replaced by [[#mLSG15|mLSG15]].''
 +
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
 
*[[Vincristine (Oncovin)]] 1 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
 
*[[Vincristine (Oncovin)]] 1 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
Line 58: Line 62:
  
 
'''28-day cycle for 7 cycles'''
 
'''28-day cycle for 7 cycles'''
−
 
+
</div></div>
 
===References===
 
===References===
−
# '''JCOG 9303:''' Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001 May;113(2):375-82. [https://doi.org/10.1046/j.1365-2141.2001.02737.x link to original article] [https://pubmed.ncbi.nlm.nih.gov/11380402 PubMed]
+
# '''JCOG 9303:''' Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001 May;113(2):375-82. [https://doi.org/10.1046/j.1365-2141.2001.02737.x link to original article] [https://pubmed.ncbi.nlm.nih.gov/11380402/ PubMed]
  
 
[[Category:Adult T-cell leukemia-lymphoma regimens]]
 
[[Category:Adult T-cell leukemia-lymphoma regimens]]

Latest revision as of 11:21, 13 May 2024

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main ATCLL page for current regimens.

2 regimens on this page
2 variants on this page


Untreated

Interferon alfa-2b & Zidovudine

Regimen

Study Dates of enrollment Evidence
Gill et al. 1995 NR Non-randomized, fewer than 20 pts

Immunotherapy

7-day cycle for up to 52 cycles or at least 4 cycles past documented CR

References

  1. Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995 Jun 29;332(26):1744-8. link to original article contains dosing details in manuscript PubMed

LSG15

Regimen

Study Dates of enrollment Evidence
Yamada et al. 2001 (JCOG 9303) 1994-1996 Phase 2

Note: Ranimustine is not available in the United States and is approved only in Japan. This regimen was notable for excess CNS relapses and was subsequently replaced by mLSG15.

Chemotherapy

Glucocorticoid therapy

28-day cycle for 7 cycles

References

  1. JCOG 9303: Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001 May;113(2):375-82. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Adult_T-cell_leukemia-lymphoma_-_historical&oldid=85428"